PureTech HealthPRTCY +1.49%62 Median PS Value is $20.06 as of Jun. 24, 2026, which is 2260% above its 10-year median of 0.85. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 276 Biotechnology companies, PureTech Health ranks worse than 68.12% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. PureTech Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.194. PureTech Health's 10-Year median PS Ratio is 103.4021. Therefore, the Median PS Value for today is $20.06.
As of today (2026-06-24), PureTech Health's share price is $17.54. PureTech Health's Median PS Value is $20.06. Therefore, PureTech Health's Price to Median PS Value for today is 0.87.
The historical rank and industry rank for PureTech Health's Median PS Value or its related term are showing as below:
PRTCY'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.82 Med: 0.85 Max: 0.87
Current: 0.87
During the past 13 years, the highest Price to Median PS Value of PureTech Health was 0.87. The lowest was 0.82. And the median was 0.85.
PRTCY's Price-to-Median-PS-Value is ranked worse than 68.12% of 276
companies
in the Biotechnology industry
Industry Median: 0.63
vs PRTCY: 0.87
PureTech Health (OTCPK:PRTCY) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
PureTech Health's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
17.54
/
20.06
=
0.87
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health Median PS Value Related Terms
PureTech Health Median PS Value Historical Data
* Premium members only.
The historical data trend for PureTech Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, PureTech Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where PureTech Health's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 103.4021.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.194.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a Median PS Value of $20.06 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PureTech Health and its competitors. This is 2260% above median its historical median of 0.85. Over the past decade, PureTech Health's Median PS Value has ranged from 0.82 to 0.87. According to the industry distribution chart, PureTech Health ranks #188 out of 276 companies in the Biotechnology industry, placing it in the top 68.1%.
Is PureTech Health's Median PS Value too high?
PureTech Health's current Median PS Value of $20.06 is 2260% above median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 0.87. The Biotechnology industry median Median PS Value is 0.63. PureTech Health's value of $20.06 is 3084.1% above this industry median. Based on the distribution chart, PureTech Health ranks #188 out of 276 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #188 out of 276 companies for Median PS Value. This places PureTech Health in the lower half of its industry. The industry median Median PS Value is 0.63. PureTech Health's value of $20.06 is 3084.1% above this benchmark. Historically, PureTech Health's own Median PS Value has ranged from 0.82 to 0.87 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.63, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Median PS Value of $20.06 is 3084.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Median PS Value is $20.06, which is 2260% above median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Median PS Value is $20.06, which is 2260% above median its 10-year median of 0.85 and 3084.1% above the Biotechnology industry median of 0.63. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Median PS Value is $20.06 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Median PS Value: $20.06 (2260% above median its 10-year median of 0.85)
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
Industry Position: 3084.1% above the Biotechnology median (#188 of 276)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
